Featured Editorial

  1. Bridging RNA Innovation: A CEO's Guide To European Expansion 10/15/2025

    For RNA biotechs, Europe isn't just the next market — it's the ultimate test of strategy. Here's what CEOs need to know.

  2. From Misinformation To Medicine: Forging Bipartisan Support to Reverse Anti-mRNA Policy 10/9/2025

    In this article, I’ll share some of the progress AMM has made and the barriers the organization/our industry is still facing in our efforts to reverse the policy decisions that have been made against mRNA today. Throughout the panel, the speakers also shared their thoughts on the types of messaging we should be considering and/or have started to see making an impact. 

  3. Beyond LNPs: 4 Non-Viral Delivery Vehicles Expanding The Possibilities Of mRNA Therapeutics 10/6/2025

    While LNPs have emerged as the most promising non-viral delivery vehicles for mRNA therapeutics thus far, the field is rapidly expanding. To broaden mRNA’s applicability across a wider range of indications, companies are exploring innovative non-viral, non-LNP delivery vehicles, including polymers, engineered virus-like particles, and more.

  4. Reclaiming mRNA's Story: How U.S. Policy Upheavals Are Pushing Us To Adapt 10/2/2025

    I’d like to believe everyone reading Advancing RNA already knows that mRNA is the greatest. So, this article isn’t going to outline why the U.S. government’s current efforts to disparage mRNA are harmful. Rather, I’d like to focus on how these policies are impacting our industry in both positive and negative ways — starting with a few takeaways I gleaned from a discussion at RNA Leaders. 

  5. What You Should Know About USP's Bioassay Updates 10/2/2025

    The United States Pharmacopeia is overhauling general chapters to align them with current industry standards. One scientist on the project helps us unpack the changes.

  6. The Death Of A Dogma: David Baltimore And Lessons For Modern Drug Discovery 9/11/2025

    Nobel laureate, David Baltimore passed away at 87 years old, on September 6, 2025. He was widely regarded as a scientific visionary who at just 37, co-discovered reverse transcriptase, an enzyme that flipped molecular biology on its head by showing that genetic information could flow from RNA back to DNA, not just the other way around. 

  7. Contract Manufacturing Outsourcing Trends For Advanced Therapies In 2025 And Beyond 9/4/2025

    Contract manufacturing continues to emerge as the widely adopted model for bringing cell therapies, gene therapies, RNA therapeutics, and oligonucleotides to patients worldwide.

  8. New Group Wants 'Phase-Appropriate' Thinking To Retire 9/4/2025

    Decisions in cell and gene therapy are not about aligning with arbitrary clinical phases but about balancing risk.

  9. The Case for Process Simplification in mRNA Manufacturing 9/2/2025

    Here, I wanted to share a few additional details from Parrella’s presentation about the efforts he and his team at Kernal Biologics made to improve their overall mRNA-LNP COGS. Though he emphasized the amount of opportunity that exists to improve our utilization of costly raw materials/reagents, as he revealed, there are also opportunities for process simplification.

  10. Can America's Retreat On mRNA Be Europe's Opportunity? 8/28/2025

    With HHS winding down mRNA vaccine development under BARDA, could Europe seize the opportunity to lead in mRNA innovation? Exploring the policy shift's implications.